Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis
Triplet-CT+anti-EGFR demonstrated no clear ORR advantage over other targeted regimens but was superior to triplet-CT alone. Preliminary data indicate a potential OS benefit. Due to increased toxicity, routine use of triplet-CT+anti-EGFR should be carefully evaluated.
Authors
- Michela Guardascione (ORCID: https://orcid.org/0000-0001-5052-3502)
- Martina Bortolot
- Paola Di Nardo (ORCID: https://orcid.org/0000-0002-8918-1201)
- Fabiola Giudici (ORCID: https://orcid.org/0000-0002-4160-3479)
- Claudia Noto
- Sara Torresan (ORCID: https://orcid.org/0009-0003-2490-0556)
- Angela Buonadonna (ORCID: https://orcid.org/0000-0002-1930-0308)
- Luisa Foltran (ORCID: https://orcid.org/0000-0002-2313-2247)
- Marco de Scordilli (ORCID: https://orcid.org/0000-0002-1219-029X)
- A Fumagalli
- Simone Rota (ORCID: https://orcid.org/0000-0002-6839-1488)
- Elena Ongaro
- Brenno Pastò
- Debora Basile
Institutions
- University of Udine (IT)
- Ospedale Maggiore (IT)
- Nuovo Ospedale San Giovanni di Dio (IT)
- Centro di Riferimento Oncologico (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1093/oncolo/oyag011
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute